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Abstract
A systematic review and meta-analysis was conducted to evaluate the comparative efficacy and
tolerability of second-generation antidepressants in social anxiety disorder. Studies were identified
by searching MEDLINE®, Embase, The Cochrane Library, PsychLit, and the International
Pharmaceutical Abstracts from January 1980 through October 2006. Comparative evidence was
summarized and indirect comparisons were made using network meta-analysis. Only three head-to-
head trials were identified; comparative trials found only minimal differences in efficacy between
escitalopram and paroxetine, and no statistically significant differences in efficacy between
extended-release venlafaxine and paroxetine. Pooled evidence from 15 placebo-controlled trials
suggests that escitalopram (relative benefit 1.3; 95% CI 1.2 to 1.5), paroxetine (relative benefit 1.9;
95% CI 1.5 to 2.3), sertraline (relative benefit 1.8; 95% CI 1.5 to 2.2), and venlafaxine (relative
benefit 1.7; 95% CI 1.5 to 1.9) all produce significantly more responders than placebo; evidence
favored fluvoxamine over placebo but was not significant (relative benefit 1.5; 95% CI 0.9 to 2.4).
Network meta-analysis did not reveal differences in efficacy among drugs. Overall, fair evidence
supports the efficacy of escitalopram, fluvoxamine, paroxetine, sertraline, and venlafaxine in social
anxiety disorder. The drugs do not differ in efficacy, although their adverse event profiles do.
Keywords
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INTRODUCTION
Social anxiety disorder (SAD), or social phobia, officially was recognized as a psychiatric
illness in 1980. The Diagnostic and Statistical Manual of Mental Disorders – fourth edition
(DSM-IV) (American Psychiatric Association, 2000) characterizes SAD as anxiety due to a
marked and persistent fear of one or more social or performance situations in which the person
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is exposed to unfamiliar people or to possible scrutiny by others. SAD may be subdivided into
generalized and nongeneralized or specific subtypes. The latter is further classified as anxiety
related to a few social or performance situations (most often public speaking). The symptoms
must interfere with a person’s normal routine, occupational functioning, relationships, or social
activities, or they must cause marked distress. Although these symptoms may be severe enough
to present in the form of a panic attack, the occurrence of such symptoms only in social
situations distinguishes SAD from panic disorder
A 1994 epidemiological study - the National Comorbidity Survey (NCS) - found SAD to be
the third most common of the psychiatric disorders (Kessler et al., 1994), trailing in prevalence
only to depression and alcohol dependence. The more recent NCS - replication survey reported
12-month prevalence of SAD to be 6.8% and the lifetime prevalence to be 12.1% (Kessler et
al., 2005). Symptoms of SAD typically onset in the middle teen years and appear more common
in women than men (Fehm et al., 2005; Westenberg and Liebowitz, 2004).
Estimating the burden of SAD is difficult because it is often accompanied by coexisting
psychiatric conditions. However, a lifetime diagnosis of SAD accounts for a 38% high school
drop-out rate, which remains significant even after controlling for age, sex, socioeconomic
status, and co-existing major depression (Stein and Kean, 2000). In one study, one-third of
patients with SAD reported suicidal ideation, and the rate of suicidal attempts was higher
among patients with major depression (Schneier et al., 1994). Perhaps the greatest burden of
SAD falls on the patient in the form of functional impairment and decreased quality of life;
this burden is difficult to quantify.
Current treatment options include pharmacologic and psychotherapeutic interventions, which
are often combined (Muller et al., 2005). Pharmacologic interventions have received increased
study as a first-line treatment (Van Ameringen and Mancini, 2001), with treatment based on
the specific subtype of SAD. “As-needed” doses of beta-blockers are prescribed for
performance-related anxiety; generalized SAD requires at least a 12-month course of scheduled
medication. Various pharmacological classes of drugs have been used to treat patients with
generalized SAD. These include beta-blockers, benzodiazepines, monoamine oxidase
inhibitors (MAOIs), and the newer antidepressant therapies sometimes referred to as second-
generation antidepressants; the latter include selective serotonin reuptake inhibitors (SSRIs),
serotonin norepinephrine reuptake inhibitors (SNRIs), and others.
As with performance-related anxiety, beta-blockers are efficacious in generalized SAD for
controlling autonomic arousal such as tachycardia, palpitations, and tremor. Although
benzodiazepines produce a beneficial anxiolytic effect, typically they are considered second-
line therapy because of physical dependence and withdrawal difficulties (Versiani, 2000).
Because of drug interactions and possible tyramine-induced hypertensive crisis necessitating
diet restrictions, MAOIs often are avoided regardless of promising efficacy (Versiani, 2000).
Certain second-generation antidepressants often are considered as first-line therapy because
of their beneficial effects and relatively benign safety profile (Davidson, 2006). Currently,
sertraline, paroxetine, and venlafaxine XR are approved by the U.S. Food and Drug
Administration (FDA) and other regulatory agencies for treating SAD. Although other agents
such as bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, and
mirtazapine have shown beneficial effects in treating related anxiety disorders, they are not
FDA approved for SAD.
Previous reviews have qualitatively and quantitatively summarized response rates for select
SSRIs and other older agents (Blanco et al., 2003; Fedoroff and Taylor, 2001; Gould et al.,
1997; Hedges et al., 2007; Stein et al., 2004; van der Linden et al., 2000). These reviews have
compared SSRIs as a class to placebo and to other classes of drugs such as MAOIs, reversible
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inhibitors of monoamine oxidase A (RIMAs), and benzodiazapines. Evidence consistently
suggests that SSRIs as a class are better than placebo. For example, the review by Van der
Linden and colleagues (van der Linden et al., 2000) found that 53% of patients responded to
an SSRI; the pooled likelihood of responding to an SSRI was 3.3 times that of responding to
placebo (95% CI 2.6 – 4.2).
One review pooled placebo-controlled data for individual SSRIs and qualitatively compared
effect sizes on various social and occupational function scales (Hedges et al., 2007). However,
this review focused on only SSRIs rather than all second-generation antidepressants and did
not evaluate comparative differences among drugs. Little is known about how newer
antidepressants compare with each other in the treatment of SAD. We improve upon previously
published systematic reviews and meta-analyses in that we focus on second-generation




Key questions designed to address the efficacy and safety of second-generation antidepressants
in treating SAD guided our work. A consortium of 14 US state Medicaid programs, the
Canadian Coordinating Office for Health Technology Assessment (CCOHTA), and the
California HealthCare Foundation helped formulate the questions and provided funding for
this research, but did not contribute to the conduct or interpretation of this review.
Literature Search
We searched MEDLINE®, Embase, The Cochrane Library, PsychLit, and the International
Pharmaceutical Abstracts. Our searches covered 1980 through October 2006. We manually
searched reference lists of relevant review articles and letters to the editor. Pharmaceutical
manufacturers were invited to submit dossiers, including citations, as outlined by the Drug
Effectiveness Review Project (Fox, 2005). We contacted the FDA and requested unpublished
studies, although the FDA did not release any unpublished data.
Study Selection
Two persons independently reviewed titles and abstracts. If both reviewers agreed that the trial
did not meet pre-established eligibility criteria (Table 1), we excluded it. We included active-
and placebo-controlled trials that randomized patients with a DSM-defined diagnosis of SAD
to bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine,
nefazodone, paroxetine, sertraline, or venlafaxine. Although observational studies with large
sample sizes can detect adverse events not frequent enough to be apparent in smaller trials, we
did not include observational evidence because of insufficient evidence specific to patients
with SAD.
Data Abstraction and Quality Assessment
Trained reviewers abstracted data from each study; a senior reviewer read each abstracted
article and evaluated completeness of data extraction. We recorded intention-to-treat results if
available. We assessed the internal validity (quality) of trials based on predefined criteria from
the US Preventive Services Task Force (ratings: good-fair-poor)(Harris et al., 2001) and the
National Health Service Centre for Reviews and Dissemination (Centre for Reviews and
Dissemination, 2001). Elements of internal validity assessment included randomization,
allocation concealment, similarity of compared groups at baseline, use of intention-to-treat
analysis, and overall and differential loss to follow-up. Loss to followup was defined as the
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number of persons randomized who did not reach the study endpoint (Egger et al., 2001),
independent of the reason and use of intention-to-treat analysis.
Data Synthesis
We abstracted data for several psychiatric rating scales including the Liebowitz Social Anxiety
Scale (LSAS) (Liebowitz, 1987), the Sheehan Disability Scale (SDS) (Leon et al., 1997), and
the Clinical Global Impression of Improvement scale (CGI-I) (Guy, 1976). The LSAS is a 24-
item scale that can be summed to create a total score; higher values of the LSAS total score
represent more severe disease. The SDS contains three domains (family, social, and work),
with higher scores in each respective domain representing more severe impairment. LSAS total
scores and each of the three domains of the SDS were coded as the mean change from baseline
to endpoint and standard deviations for the mean change. When standard errors or standard
deviations were not reported, we imputed values using estimates from similarly designed trials.
Treatment response was coded as the number of patients characterized as 1 “very much” or 2
“much” improved on the CGI-I at endpoint.
We first qualitatively summarized the studies. For rating scales that were consistently used
across trials (i.e., LSAS and CGI-I), we did quantitative analyses. For the LSAS we calculated
the overall size of effect for a treatment. When we had two or more trials for a single drug, we
used the pooled sample standard deviation (Hedges and Olkin, 1985) to calculate a pooled
weighted mean difference. For the CGI-I we calculated the likelihood of treatment response
using a relative risk (risk ratio) meta-analysis. Because this analysis reflects benefits rather
than risks, we report this as a relative benefit (RB). When trials included multiple dosing arms,
we included the highest FDA-approved dose. For studies with an active comparator, we
analyzed each drug separately but reduced the sample size of the placebo group proportionately
(e.g., for studies with two active treatments and placebo, the placebo sample size was halved
for each comparison so as not to double count). For each meta-analysis we tested for
heterogeneity of treatment effects by using I2 statistics (Higgins et al., 2003). If heterogeneity
appeared we explored potential reasons for inconsistency. To estimate possible publication
bias caused by the tendency of published studies to be positive, we used funnel plots, the Begg
adjusted rank correlation test (Begg and Mazumdar, 1994), and the Egger regression approach
(Egger et al., 1997).
Because no head-to-head evidence was available for the majority of drug comparisons, we
conducted indirect comparisons using network meta-analysis (Lumley, 2002) of placebo-
controlled trials. This method assesses the relative benefits of two treatments when they have
not been compared directly with each other, but have each been compared to other treatments
(Lumley, 2002). Evidence suggests that indirect comparisons agree with head-to-head trials if
component studies are similar and treatment effects are expected to be consistent in patients
included in different trials (Glenny et al., 2005). The outcome of this analysis was the CGI-I,
with response categorized as improved or very much improved on the CGI-I. Individual drugs
were included in the network meta-analysis when at least two similarly designed trials provided
CGI-I data.
For adverse events we calculated the pooled mean incidence and 95% confidence intervals
(CIs) from included trials. We focused on events previously documented with the drugs of
interest in treating major depression (Hansen et al., 2005), such as nausea, vomiting, diarrhea,
headache, dizziness, insomnia, sexual side effects, and weight gain.
Statistical analyses used StatsDirect Statistical Software, version 2.3.8 (StatsDirect, Ltd.,
Cheshire, UK, 2004) and R (Free Software Foundation, Inc., Boston, MA, 2007).
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Three head-to-head trials (Allgulander et al., 2004; Lader et al., 2004; Liebowitz et al., 2005)
and 15 placebo-controlled trials (Allgulander, 1999; Baldwin et al., 1999; Blomhoff et al.,
2001; Davidson et al., 2004; Kasper et al., 2005; Kobak et al., 2002; Lepola et al., 2004;
Liebowitz et al., 2003; Rickels et al., 2004; Stein et al., 1999; Stein et al., 1998; Stein et al.,
2005; Van Ameringen et al., 2001; Wagner et al., 2004; Westenberg et al., 2004) were included
(see Appendix 1). We excluded five trials: one because it assessed relapse prevention (Stein
et al., 2003); one because it did not assess the LSAS, CGI-I, or SDS (van Vliet et al., 1994);
one because it lasted less than 12 weeks (Katzelnick et al., 1995); and two trials because they
did not meet our pre-defined quality criteria (Allgulander and Nilsson, 2001; Martins et al.,
1994). Included trials lasted from 12 to 28 weeks. The mean age in most trials was between
35 and 45 years, with a relatively equal distribution of males and females (Table 2). One study
included children and adolescents (mean age, 13 years) (Wagner et al., 2004). Although all
trials required a diagnosis of SAD consistent with the DSM-IV, trials varied with regard to
baseline severity of disease; mean baseline LSAS scores ranged from 74 (Allgulander, 1999)
to 96 (Kasper et al., 2005). Some studies included patients with coexisting psychiatric
conditions.
Clinical Response: Anxiety Severity
Two trials that compared venlafaxine with paroxetine (Allgulander et al., 2004; Liebowitz et
al., 2005) and one trial that compared escitalopram with paroxetine (Lader et al., 2004) reported
LSAS measures. No statistically significant differences in the reduction in LSAS scores were
reported between venlafaxine and paroxetine. Mean doses of venlafaxine and paroxetine were
generally comparable. Statistically significantly larger differences were noted for patients on
higher doses (i.e., 20mg/day) of escitalopram compared with paroxetine 20mg/day in observed
cases analysis, although these were not statistically significant in the intention to treat analysis.
Differences were not statistically significant for lower doses of escitalopram in either the
observed cases or intention to treat analysis.
We abstracted usable data for the mean reduction in LSAS total score for 14 trials, representing
16 placebo-controlled comparisons. Data were sufficient to calculate a pooled weighted mean
difference between placebo and escitalopram, fluvoxamine, paroxetine, and venlafaxine
(Figure 1). Overall for these pooled data, active treatments lead to a 10 to 16 point greater
LSAS reduction than placebo. The pooled weighted mean difference was 10.3 (95% CI 5.9 to
14.6) for escitalopram, 12.3 (95% CI 8.2 to 16.3) for fluvoxamine, 16.1 (95% CI 13.1 to 19.1)
for paroxetine, and 14.8 (10.6 to 19.0) for venlafaxine. Only minimal heterogeneity was
detected and tests for publication bias were not significant.
Clinical Response: Functional Impairment
Two trials that compared venlafaxine with paroxetine (Allgulander et al., 2004; Liebowitz et
al., 2005) and one trial that compared escitalopram with paroxetine (Lader et al., 2004) assessed
disability using the SDS. Active treatments did not differ significantly in reducing disability
from SAD.
We abstracted data for the mean reduction in family, social, and work domains of the SDS
from 12 trials including 13 different placebo-controlled comparisons (i.e., 1 head-to-head trial
provided usable data); 2 trials of escitalopram, 3 of fluvoxamine, 5 of paroxetine, 2 of sertraline,
and 1 of venlafaxine. Active treatment was statistically significantly better than placebo on the
work domain of the SDS in all trials (P < 0.05). Compared with placebo, active treatment
produced a 0.7 to 2.2 point greater reduction in the work domain (pooled difference 1.25; 95%
CI 0.9 to 1.5). The social domain was significantly more improved for active treatment
Hansen et al. Page 5













compared with placebo in all but one trial; the trial that failed to show statistically significant
differences compared controlled-release fluvoxamine to placebo over 12 weeks (Westenberg
et al., 2004). Overall, the weighted mean difference between active treatment and placebo for
the reduction in the social domain of the SDS ranged from 0.5 to 1.9 (pooled difference 1.16;
95% CI 0.9 to 1.4). Trends toward greater improvement in the family domain for active
treatment compared with placebo were observed in most trials, although this difference did not
reach statistical significance in six trials (escitalopram (Kasper et al., 2005); fluvoxamine
(Westenberg et al., 2004); paroxetine (Lader et al., 2004; Stein et al., 1998); sertraline
(Blomhoff et al., 2001); and venlafaxine (Rickels et al., 2004)). The weighted mean difference
between active treatment and placebo for the family domain ranged from 0 to 1.7 (pooled
difference 0.86; 95% CI 0.6 to 1.1). Only minimal heterogeneity was detected and tests for
publication bias were not significant.
Clinical Response: Global Impression
We abstracted CGI-I response data on active treatment and placebo from 18 trials. Responders
were characterized by a rating of 1 “very much” or 2 “much” improved on the CGI-I. The
pooled relative benefit of most drugs was positive; approximately 30 to 85 percent more
patients that received active treatment achieved response than did those that received placebo
(Figure 2). The pooled relative benefits for escitalopram (RB 1.31; 95% CI 1.17 to 1.46),
paroxetine (RB 1.85; 95% CI 1.49 to 2.29), sertraline (RB 1.78; 95% CI 1.45 to 2.16), and
venlafaxine (RB 1.68; 95% CI 1.47 to 1.93) were statistically significantly better than placebo.
Tests for publication bias were not significant. Substantial heterogeneity was detected in the
meta-analysis of placebo-controlled paroxetine trials (I2 = 82%). We explored whether this
heterogeneity was related to a single trial that reported unusually large differences between
paroxetine and placebo (Allgulander, 1999). Comparing this trial with other paroxetine trials,
the inconsistency may be related to the fact that this trial was relatively small and, on average,
patients had less severe anxiety (mean baseline LSAS = 74). As a sensitivity analysis, removing
this trial did not significantly change the pooled relative benefit (RB without Allgulander et
al. (1999) 1.77; 95% CI 1.62 to 1.92; RB with Allgulander et al. (1999) 1.85; 95% CI 1.49 to
2.29). The I2 statistic remained relatively large after removing this trial (I2 = 80.9%), suggesting
additional inconsistencies among trials.
Two trials that directly compared venlafaxine with paroxetine (Allgulander et al., 2004;
Liebowitz et al., 2005) and one trial that compared escitalopram with paroxetine (Lader et al.,
2004) assessed CGI-I response. The numbers of responders did not differ significantly for
either comparison. Our network meta-analysis (Figure 3) also found no significant differences
for either of these comparisons or for any of the other possible comparisons among
escitalopram, fluvoxamine, paroxetine, sertraline, or venlafaxine. However, confidence
intervals for the indirect comparisons were large and likely are not able to detect small but
potentially clinically significant differences.
Adverse Events
Methods used to assess adverse events and the quality of reporting of specific events differed
among studies. In most trials, open-ended questioning was used to elicit adverse events, leading
to great variability in the quantity and quality of reporting. The pooled mean incidence and
95% CIs of common adverse events reported in randomized controlled trials are shown in Table
3. The most commonly reported adverse events were nausea, asthenia (i.e., loss of energy or
strength) or fatigue, or changes in sleep. In general, the types of adverse events reported among
patients with SAD are similar to those reported in patients with other psychiatric diseases such
as major depressive disorder (Hansen et al., 2005), although the trends in the incidence of
certain adverse events were generally higher in these patients. For instance, nausea was
reported by 25% to 39% of patients with social anxiety while the observed rate was between
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15% and 31% in patients with major depression. Similarly, as many as 47% of patients with
SAD reported insomnia; the observed incidence for patients with major depression disorder
was between 10% and 15% (Hansen et al., 2005).
DISCUSSION
Fair evidence suggests that several second-generation antidepressants are effective treatments
for patients with SAD. Currently, sertraline, paroxetine, and venlafaxine are approved by the
FDA and other regulatory agencies for SAD; limited evidence from our review also supports
the efficacy of escitalopram and fluvoxamine. Only one study assessed the efficacy and safety
of fluoxetine (Kobak et al., 2002), and no study was identified for bupropion, citalopram,
duloxetine, or mirtazapine.
Consistent with the meta-analyses by van der Linden and colleagues (van der Linden et al.,
2000) and Hedges and colleagues (Hedges et al., 2007), our review found relatively strong
evidence supporting clinical response (i.e., CGI-I) and improvement in social anxiety
assessments. Across trials, 40% to 85% of patients randomized to escitalopram, fluvoxamine,
paroxetine, sertraline, or venlafaxine were characterized as CGI-I responders. Thus, from the
clinician’s perspective, 40% to 85% had a clinically significant improvement.
Similarly, LSAS scores improved by an average of 34 points across trials, representing roughly
a 40% improvement. Reductions in LSAS scores of 20% to 30% from baseline have previously
been defined as clinically significant (Liebowitz, 2005). Overall, the mean reduction in LSAS
scores was roughly 10 to 15 points greater for escitalopram, fluvoxamine, paroxetine,
sertraline, and venlafaxine than placebo, representing approximately a 20% greater reduction
in LSAS scores than placebo.
Head-to-head trials (Allgulander et al., 2004; Lader et al., 2004; Liebowitz et al., 2005) did not
identify significant differences in efficacy for escitalopram compared with paroxetine or
venlafaxine compared with paroxetine. Although patients treated with the highest dose of
escitalopram (20mg/day) had statistically significantly greater improvements in LSAS total
scores than paroxetine-treated patients (20mg/day) in an observed cases analysis, these results
were not statistically significant in the ITT analysis (Lader et al., 2004). Our network meta-
analysis also found that escitalopram, fluvoxamine, paroxetine, sertraline, and venlafaxine do
not differ with regard to clinician’s global assessment of improvement. Thus, given available
evidence, these drugs do not appear to differ with regard to efficacy.
Although our intent was not to compare these drugs to other types of pharmacotherapy or
cognitive-behavioral therapy, our results can be put in context of such studies. For example, a
Cochrane Collaboration review (Stein et al., 2000) concluded that SSRIs were significantly
more effective than moclobemide and brofaromine (RIMAs). Fedoroff and Taylor (Fedoroff
and Taylor, 2001) found SSRIs and benzodiazepines to be better than psychotherapies in
improving various outcome measures.
Our analysis of SDS scores found relatively consistent reduction (i.e., improvements) for the
work and social domains for escitalopram, fluvoxamine, paroxetine, sertraline, and
venlafaxine. Reductions observed in the family domain of the SDS were marginally significant,
although the mean difference in this measure was more inconsistent across trials compared to
the work and social domains. This is likely related to the nature of the disease. Patients with
SAD generally have little dysfunction in the family domain of function and little room for
improvement with treatment. In contrast, SAD symptoms often interfere with a person’s normal
routine, occupational functioning, relationships, and social activities. These symptoms are
likely to be reflected in the work and social domains of the SDS, but not in the family domain.
This point is illustrated by the baseline domain-specific scores across trials included in our
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analysis; average scores were 3.3 for family, 6.8 for social, and 5.4 for work. Given better
baseline scores for the family domain compared to the social and work domains, our finding
that the family domain did not consistently improve makes sense.
We observed a general trend toward a higher incidence of certain adverse events among patients
with SAD than has been previously reported among patients with major depressive disorder
(Hansen et al., 2005). This observation may be spurious, however, because our analysis
consisted of fewer component studies than the number of studies analyzed in patients with
major depressive disorder. The nature of SAD itself or the patients prone to this disease may
well differ from that for patients with major depressive disorder, and this finding needs to be
investigated further. Side effects commonly reported in major depressive disorder, such as
dizziness, headache, and weight gain, were not consistently assessed or reported in social
anxiety trials, so conclusions in this regard are limited.
Although systematic reviews help eliminate some sources of bias, limitations must be
considered. First, we are limited by the quantity and quality of evidence available. We found
only three fair- or good-rated comparative trials, and placebo-controlled trials were too few in
number to conduct reliable indirect comparisons. We used network meta-analysis (Glenny et
al., 2005; Lumley, 2002) to pool head-to-head trials with placebo controlled trials so that we
could compare different treatments indirectly. To date this method has not been commonly
used for making drug-drug comparisons. Additionally, because of the small number of
component studies, this analysis is imprecise – as reflected by our wide confidence intervals.
Doses and dosing designs varied among studies included in quantitative analyses. All included
studies represented a range of doses deemed to be clinically relevant. Among fixed dose studies,
we analyzed only the highest dosing arm approved by regulatory authorities. Although this
method avoids the risk of including sub-therapeutic doses, it may overestimate the actual
treatment effect. In our quantitative analyses, we attempted to assess the degree of publication
bias (higher publication rates among studies that show a statistically significant effect of
treatment) but these methods are of low statistical power given the limited number of trials
published for each drug. Another limitation is incomplete trial reporting and differences in
outcome measures utilized in trials. For example, although 14 trials provided data for total
LSAS score, only 6 of these trials reported complete data on the fear/anxiety and avoidance
subscales. We requested unpublished data from the FDA and manufacturers of included drugs
but had to exclude unpublished studies because abstracts or summaries did not provide enough
information to allow critical appraisal of the study.
Overall, fair evidence supports statistically significant benefits for escitalopram, fluvoxamine,
paroxetine, sertraline, and venlafaxine in patients with SAD. Aside from documented
differences in the incidence of specific adverse events, existing evidence does not suggest
differences in efficacy for these drugs.
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Liebowitz social anxiety scale meta-analysis (random effects)
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Clinical global impression of improvement meta-analysis (random effects)
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Indirect comparisons of second-generation antidepressants
* Outcome defined as “much” or “very much” improved on the clinical global impression of
improvement scale
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Table 1
Systematic review inclusion and exclusion criteria
Outcome Inclusion Exclusion Criteria
Efficacy / Effectiveness
• Randomized, controlled trials
comparing one second-generation
antidepressant to another second-
generation antidepressant or
placebo
• Statistically significant differences
between treatment groups deemed to
affect outcomes (e.g., baseline severity
of illness)
• Study duration 12 weeks or longer • Fatal flaws in study design or data
analysis that contribute to a “poor”
quality rating for internal validity
• Adult and pediatric outpatients
• Outcomes include: Liebowitz
Social Anxiety Scale, Clinical
Global Impression of
Improvement scale, or the
Sheehan Disability Scale
Safety / Tolerability
• Randomized, controlled trials
comparing one second-generation
antidepressant to another second-
generation antidepressant or
placebo
• Statistically significant differences
between treatment groups deemed to
affect outcomes (e.g., baseline severity
of illness)
• Study duration 12 weeks or longer • Fatal flaws in study design or data
analysis that contribute to a “poor”
quality rating for internal validity
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